Samsung Biologics and Checkpoint Therapeutics Expand Manufacturing Partnership for Cosibelimab
- Monday, November 2, 2020, 7:03
- Finance
- Add a comment
INCHEON, South Korea and NEW YORK, Nov. 2, 2020 /PRNewswire/ — Samsung Biologics Co., Ltd. (“Samsung Biologics”) (KRX: 207940.KS) and Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), today announced the expansion of a long-term manufacturing partnership for Checkpoint’s…
About the Author
adminasapcorp has written 39120 stories on this site.